2. Search Result
Search Result
Results for "

Arginine vasopressin

" in MedChemExpress (MCE) Product Catalog:

26

Inhibitors & Agonists

14

Peptides

1

Natural
Products

2

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P3066
    SKF 100398

    d(CH2)5Tyr(Et)VAVP

    		 Vasopressin Receptor Metabolic Disease
    SKF 100398 (d(CH2)5Tyr(Et)VAVP), an arginine vasopressin (AVP) analogue, is a specific antagonist of the antidiuretic effect of exogenous and endogenous AVP .
    SKF 100398
  • HY-10066
    Nelivaptan

    SSR-149415

    		 Vasopressin Receptor Neurological Disease
    Nelivaptan (SSR-149415) is a selective and orally active vasopressin V1b Receptor antagonist (Ki: 3.7 and 1.3 nM for native and recombinant rat V1b receptors, respectively). Nelivaptan inhibits arginine vasopressin (AVP)-induced Ca 2+ increase and corticotropin secretion. Nelivaptan can be used for research of stress and anxiety .
    Nelivaptan
  • HY-117820
    TASP0390325

    		Vasopressin Receptor Neurological Disease
    TASP0390325 is a high affinity and orally active arginine vasopressin receptor 1B (V1B receptor) antagonist with antidepressant and anxiolytic activities .
    TASP0390325
  • HY-P0049
    Argipressin
    Maximum Cited Publications
    12 Publications Verification

    Arg8-vasopressin; AVP

    		 Vasopressin Receptor Neurological Disease Cancer
    Argipressin (Arg8-vasopressin) binds to the V1, V2, V3-vascular arginine vasopressin receptor, with a Kd value of 1.31 nM in A7r5 rat aortic smooth muscle cells for V1.
    Argipressin
  • HY-106102
    [Deglycinamide9, Arginine8]-Vasopressin

    		Endogenous Metabolite Cardiovascular Disease
    [Deglycinamide9, Arginine8]-Vasopressin is a Vasopressin (HY-B1811) analog. [Deglycinamide9, Arginine8]-Vasopressin induces platelet aggregation. [Deglycinamide9, Arginine8]-Vasopressin has hemostatic effect .
    [Deglycinamide9, Arginine8]-Vasopressin
  • HY-W539944
    Argipressin acetate

    Arg8-vasopressin acetate; AVP acetate

    		 Vasopressin Receptor Apoptosis Neurological Disease
    Argipressin (Arg8-vasopressin) (acetate) binds to the V1, V2, V3-vascular arginine vasopressin receptor, with a Kd value of 1.31 nM in A7r5 rat aortic smooth muscle cells for V1 .
    Argipressin acetate
  • HY-129333
    L-364918

    		Oxytocin Receptor Vasopressin Receptor Metabolic Disease
    L-364918 is a potent and selective oxytocin and arginine vasopressin antagonist with Ki values of 30, 1300, 2400 nM for OT, AVP-V1, AVP-V2, respectively. L-364918 has the potential for the research of preterm labor and disturbances in water balance .
    L-364918
  • HY-P3213
    Dp[Tyr(methyl)2,Arg8]-Vasopressin

    		Vasopressin Receptor Metabolic Disease
    Dp[Tyr(methyl)2,Arg8]-Vasopressin is a non-selective peptide arginine vasopressin Vlb receptor antagonist .
    Dp[Tyr(methyl)2,Arg8]-Vasopressin
  • HY-P4237
    [8-L-arginine] deaminovasopressin

    dAVP

    		 Vasopressin Receptor Others
    [8-L-arginine] deaminovasopressin (dAVP) is a vasopressin analog .
    [8-L-arginine] deaminovasopressin
  • HY-162394
    Vasopressin V2 receptor antagonist 2

    		Vasopressin Receptor Metabolic Disease
    Vasopressin V2 receptor antagonist 2 (Compound 33) is an antagonist of the arginine vasopressin V2 receptor (V2R) with a Ki value of 6.2 nM. Vasopressin V2 receptor antagonist 2 can effectively reduce cAMP levels, thereby inhibiting the growth of renal cysts[1].
    Vasopressin V2 receptor antagonist 2
  • HY-P10046
    [Deamino-Pen1,Val4,D-Arg8]-vasopressin

    		Vasopressin Receptor Metabolic Disease
    [Deamino-Pen1,Val4,D-Arg8]-vasopressin (AVP-A) is an arginine-vasopressin (AVP) antagonist. AVP-A can significantly lower plasma aldosterone concentration in rats. AVP-A can be used for the research of the growth and steroidogenic capacity of rat adrenal zona glomerulosa .
    [Deamino-Pen1,Val4,D-Arg8]-vasopressin
  • HY-157220
    Tolvaptan phosphate ester sodium

    		Vasopressin Receptor Cardiovascular Disease
    Tolvaptan phosphate ester sodium, a prodrug of Tolvaptan (HY-17000), can be used in the study of cardiac edema. Tolvaptan is a selective, competitive and orally active vasopressin receptor 2 (V2R) antagonist with an IC50 of 1.28 μM for the inhibition of arginine vasopressin (AVP)-induced platelet aggregation .
    Tolvaptan phosphate ester sodium
  • HY-17000
    Tolvaptan
    5+ Cited Publications

    OPC-41061

    		 Vasopressin Receptor Autophagy Cardiovascular Disease Endocrinology Cancer
    Tolvaptan is a selective, competitive and orally active vasopressin receptor 2 (V2R) antagonist with an IC50 of 1.28 μM for the inhibition of arginine vasopressin (AVP)-induced platelet aggregation. Tolvaptan induces cell apoposis and affects cell cycle. Tolvaptan can be used for the research of hyponatremia .
    Tolvaptan
  • HY-P1747
    Pneumadin, rat

    PNM

    		 Others Metabolic Disease
    Pneumadin, rat (PNM) is a decapeptide, which possess a potent stimulating effect on arginine-vasopressin (AVP) release. Pneumadin, rat (PNM) exerts a marked antidiuretic effect in animals with functional AVP system .
    Pneumadin, rat
  • HY-P5007
    Copeptin (human)

    		Biochemical Assay Reagents Cardiovascular Disease
    Copeptin (human) is a diagnostic and prognostic biomarker for cardiovascular disease (CVD). Copeptin (human) is also the carboxyl terminus of the arginine vasopressin (AVP) precursor peptide. Copeptin (human) can be used in the study of cardiovascular disease .
    Copeptin (human)
  • HY-17000R
    Tolvaptan (Standard)

    		Vasopressin Receptor Autophagy Cardiovascular Disease Endocrinology Cancer
    Tolvaptan (Standard) is the analytical standard of Tolvaptan. This product is intended for research and analytical applications. Tolvaptan is a selective, competitive and orally active vasopressin receptor 2 (V2R) antagonist with an IC50 of 1.28 μM for the inhibition of arginine vasopressin (AVP)-induced platelet aggregation. Tolvaptan induces cell apoposis and affects cell cycle. Tolvaptan can be used for the research of hyponatremia .
    Tolvaptan (Standard)
  • HY-17000S
    Tolvaptan-d7

    		Isotope-Labeled Compounds Vasopressin Receptor Autophagy Cardiovascular Disease Endocrinology Cancer
    Tolvaptan-d7 is the deuterium labeled Tolvaptan. Tolvaptan is a selective, competitive arginine vasopressin receptor 2 antagonist with an IC50 of 1.28μM for the inhibition of AVP-induced platelet aggregation[1][2].
    Tolvaptan-d7
  • HY-18346
    Mozavaptan
    1 Publications Verification

    OPC-31260

    		 Vasopressin Receptor Metabolic Disease Endocrinology Cancer
    Mozavaptan (OPC-31260) is a benzazepine derivative and a potent, selective, competitive and orally active vasopressin V2 receptor antagonist with an IC50 of 14 nM. Mozavaptan shows ~85-fold selectivity for V2 receptor over V1 receptor (IC50 of 1.2 μM), and can antagonize the antidiuretic action of arginine vasopressin (AVP) in vivo. Mozavaptan has the potential for hyponatremia, syndrome of inappropriate antidiuretic hormone (SIADH), and congestive heart failure treatment .
    Mozavaptan
  • HY-123593
    Mozavaptan hydrochloride
    1 Publications Verification

    OPC-31260 hydrochloride

    		 Vasopressin Receptor Metabolic Disease Endocrinology Cancer
    Mozavaptan hydrochloride (OPC-31260 hydrochloride) is a benzazepine derivative and a potent, selective, competitive and orally active vasopressin V2 receptor antagonist with an IC50 of 14 nM. Mozavaptan hydrochloride shows ~85-fold selectivity for V2 receptor over V1 receptor (IC50 of 1.2 μM), and can antagonize the antidiuretic action of arginine vasopressin (AVP) in vivo. Mozavaptan hydrochloride has the potential for hyponatremia, syndrome of inappropriate antidiuretic hormone (SIADH), and congestive heart failure treatment .
    Mozavaptan hydrochloride
  • HY-103023
    CLP290
    1 Publications Verification

    		 Potassium Channel Neurological Disease
    CLP290 is an orally available activator of the neuron-specific K +-Cl ? cotransporter KCC2, displays potential for treatment of a wide range of neurological and psychiatric indications. CLP290 can significantly lower blood arginine-vasopressin (AVP) and glucose levels in STZ (HY-13753) rats .
    CLP290
  • HY-P0049A
    Argipressin diacetate

    Arg8-vasopressin diacetate; AVP diacetate; ADH

    		 Apoptosis Vasopressin Receptor Neurological Disease
    Argipressin (diacetate) (AVP (diacetate), also known as antidiuretic hormone (ADH)) is a 9 amino acid neuropeptide secreted by the posterior pituitary. Argipressin (diacetate) (AVP (diacetate)) can regulate the biological effects of fluid balance, osmolality and cardiovascular through three separate G-protein coupled receptors (GPCRs), namely Avpr1a (V1a), Avpr1b (V1b) and Avpr2 (V2). Argipressin (diacetate) (AVP (diacetate)) also have potentially important effects on centrally regulated metabolic processes .
    Argipressin diacetate
  • HY-18346S
    Mozavaptan-d6

    OPC-31260-d6

    		 Isotope-Labeled Compounds Vasopressin Receptor Metabolic Disease Endocrinology Cancer
    Mozavaptan-d6 (OPC-31260-d6) is the deuterium labeled Mozavaptan. Mozavaptan (OPC-31260) is a benzazepine derivative and a potent, selective, competitive and orally active vasopressin V2 receptor antagonist with an IC50 of 14 nM. Mozavaptan shows ~85-fold selectivity for V2 receptor over V1 receptor (IC50 of 1.2 μM), and can antagonize the antidiuretic action of arginine vasopressin (AVP) in vivo. Mozavaptan has the potential for hyponatremia, syndrome of inappropriate antidiuretic hormone (SIADH), and congestive heart failure treatment .
    Mozavaptan-d6
  • HY-19115
    YM-430

    		Calcium Channel Adrenergic Receptor Cardiovascular Disease
    YM-430 is an oral active calcium entry-blocking and beta-adrenoceptor-blocking agent. YM-430 inhibits Amifampridine (HY-14946)-induced rhythmic contractions with an IC50 value of 59.2 nM and inhibits arginine vasopressin-induced ST-segment depression with an IC50 value of 36.6 mg/kg. YM-430 can be used for study of angina pectoris .
    YM-430
  • HY-A0182
    Felypressin
    3 Publications Verification

    PLV-2

    		 Vasopressin Receptor Cardiovascular Disease
    Felypressin (PLV-2) is a non-catecholamine vasoconstrictor and a vasopressin 1 agonist. Felypressin is widely used in dental procedures .
    Felypressin
  • HY-A0182A
    Felypressin acetate
    3 Publications Verification

    PLV-2 acetate

    		 Vasopressin Receptor Cardiovascular Disease
    Felypressin acetate (PLV-2 acetate) is a non-catecholamine vasoconstrictor and a vasopressin 1 agonist. Felypressin acetate is widely used in dental procedures .
    Felypressin acetate
  • HY-15007
    L 366509

    		Oxytocin Receptor Endocrinology
    L 366509 is a spiroindenylpiperidine camphorsulfonamide oxytocin (OT) antagonist. Modifications led to a new series of o-tolylpiperazine (TP) camphorsulfonamides, exhibiting high affinity for OT receptors and selectivity over arginine vasopressin receptors. Notably, compound 7 (L-368,899) showed excellent OT receptor affinity, potency in inhibiting OT-stimulated uterine contractions, good aqueous solubility, and oral bioavailability in multiple species. Compound 7 has entered clinical testing as an oral and intravenous tocolytic agent. Molecular modeling suggests the TP camphorsulfonamide structure mimics the D-AA2-Ile3 dipeptide, crucial in potent OT antagonists .
    L 366509

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: